Strong financial position with cash, cash equivalents and marketable securities of $93.7M   Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025   Additional analysis of imdusiran (AB-729) clinical data shows:– 46% of Phase 2a patients met criteria to discontinue all treatment– 94% of long-term follow-up patients remain off all treatment for up to 2+ years– 100% of HBV DNA positive patients in Phase 1b achieved HBV DNA levels belowquantification after only 18 weeks of imdusiran and nucleos(t)ide analogue therapy– All HBV e-antigen positive patients demonstrated dose-dependent HBV e-antigen decreases   WARMINSTER, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation...

OMAHA, NE, Nov. 13, 2025 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the third quarter ended September 30, 2025. Highlights for the third quarter ended September 30, 2025 include:On August 8, 2025, the Company completed the acquisition of substantially all of the assets of Irwin Naturals (“Irwin”), and Irwin’s operating results for the period of August 9 through September 30 are included in FitLife’s consolidated financials for the third quarter of 2025. Total revenue was $23.5 million, an increase of 47% compared to the third quarter of 2024.   Wholesale revenue was $13.2 million, representing 56% of revenue and an increase of 156% compared to the third quarter...

Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Ascletis announced completion of its pre-NDA consultation with China’s NMPA and plans to submit an NDA for denifanstat in China for treatment of moderate-to-severe acne vulgaris SAN MATEO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended September 30, 2025, and provided recent corporate updates. “This is a dynamic period for Sagimet as we explore the therapeutic potential of FASN inhibition across different...

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden  Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and showing efficient masking, potent anti-tumor activity and broad therapeutic index Anticipate cash runway into the first quarter of 2027 WALTHAM, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people...

Very strong order momentum, with third quarter order intake up 33% year-over-year Order backlog increased by another 6% since June 2025, supporting 2026 growth ambitions Group net sales of $471m, up 3% year-over-year, with expected significant growth in fourth quarter Adjusted EBITDA1 of $42.2m or 9.0% adjusted EBITDA margin, up 25% year-over-year with a 160 basis-point margin improvement Synergies materialization accelerated, supporting upper end of increased target of $40mFRAUENFELD, Switzerland,, Nov. 13, 2025 (GLOBE NEWSWIRE) — Aebi Schmidt Group (NASDAQ: AEBI) (“Aebi Schmidt” or the “Company”), a world-class specialty vehicles leader, reports significant step-up in profitability following the acquisition of the Shyft Group. “The entire new Aebi Schmidt Group has been focusing on executing the integration and realizing the...

CICERO, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) — Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the third quarter 2025. THIRD QUARTER 2025 RESULTS(As compared to the third quarter 2024)Total revenue of $44.2 million, +25% y/y GAAP net income of $7.5 million, or $0.32 per diluted share Non-GAAP Adjusted EBITDA of $2.4 million, excluding the $8.2 million gain on the sale of industrial fabrication operations on September 8, 2025 Total orders of $43.6 million, +90% y/y Raising full-year 2025 revenue guidanceMANAGEMENT COMMENTARY “This year, our team continued to transform Broadwind into a leading precision manufacturing partner of choice to global OEMs,” stated Eric Blashford, President and CEO of Broadwind....

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2025. Summary of Financial Results & Recent Progress:Energy Based Device (“EBD”) revenues showing signs of stabilization.Total EBD systems sales of $9.6 million, up 2% year over yearTotal revenue for the third quarter of $13.8 million, down 8% year-over-year and down 12% quarter-over-quarter.Primarily driven by a decline in the Hair Restoration business (the “Venus Hair Business”) impacted by a delay in the pending sale.Third quarter GAAP net loss of $22.5 million, compared to $9.3 million last year. Excluding loss on debt extinguishment, loss on disposal of subsidiaries and restructuring...

Accelerating profitable growth and building a new TAD tissue facility to start-up in 2028 MISSISSAUGA, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q3 2025 financial and operational results of KPT and Kruger Products Inc. (Kruger Products or the Company). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and Bonterra®) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.1% interest in Kruger Products. Kruger Products Q3 2025 Business and Financial HighlightsRevenue was $561.1 million in Q3 2025 compared to $521.1 million in Q3 2024, an increase...

The Company Achieves a 7% Increase in YTD Production, Reduces Net Debt, and Maintains Production and Capital Expenditure Guidance Ranges CALGARY, Alberta, Nov. 13, 2025 (GLOBE NEWSWIRE) — Bonterra Energy Corp. (TSX: BNE) (“Bonterra” or the “Company”) is pleased to announce its financial and operating results for the three and nine months ended September 30, 2025. The related unaudited condensed financial statements and notes for the third quarter, as well as management’s discussion and analysis (“MD&A”), are available on SEDAR+ at www.sedarplus.ca and on Bonterra’s website at www.bonterraenergy.com. FINANCIAL AND OPERATIONAL HIGHLIGHTS    Three months ended Nine months endedAs at and for the periods ended ($ 000s except for $ per share and $ per BOE) September 30,2025   September 30,2024 September 30,2025   September...

Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other assets acquired Significant cost reductions quarter over quarter NEWTOWN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the quarter ended September 30, 2025 and provided recent business highlights for its antiviral programs. Recent Highlights and Anticipated Milestones: Product Development Ratutrelvir (COVID): Potential best-in-class therapy to minimize the risk of viral...